Response to: ‘Letter to the Editor: “Management of multidrug-resistant Pseudomonas aeruginosa in the Intensive Care Unit: state of the art”’
Sign Up to like & getrecommendations! Published in 2018 at "Expert Review of Anti-infective Therapy"
DOI: 10.1080/14787210.2018.1473082
Abstract: Dear Editor, We truly thank Dr Plant and colleagues for taking an interest in our review, raising an important issue about the risk of resistance development and clinical failure when ceftolozane/tazobactam (TOL/TAZ) is used against… read more here.
Keywords: taz; beta; resistance; activity ... See more keywords
Comparative in vitro Activities of Ceftazidime–Avibactam and Ceftolozane-tazobactam Against Characterized β-Lactamase-producing Pseudomonas aeruginosa
Sign Up to like & getrecommendations! Published in 2017 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofx163.897
Abstract: Abstract Background Ceftazidime-avibactam (CAZ-AVI) and ceftolozane-tazobactam (TOL-TAZ) are cephalosporin/β-lactamase inhibitor combinations recently approved for the treatment of complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI). Both agents are reported to have antibacterial activity… read more here.
Keywords: lactamase; caz avi; tol taz; lactamase producing ... See more keywords